Identification and characterization of mGlu3 ligands using a high throughput FLIPR assay for detection of agonists, antagonists, and allosteric modulators

Combinatorial Chemistry and High Throughput Screening

Volumn 14, Issue 7, 2011, Pages 631-641

  Pratt, Steven D ^a   Mezler, Mario ^b   Geneste, Herv́ ^b   Bakker, Margot H M ^b   Hajduk, Philip J ^a   Gopalakrishnan, Sujatha M ^a  

^a ABBOTT LABORATORIES   (United States)

^b ABBOTT GMBH AND CO KG   (Germany)

Author keywords

FLIPR; GPCR; High throughput; MGlu3; MGluR3; Triple addition

Indexed keywords

2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; 4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; ADENOSINE 5' (N ETHYLCARBOXAMIDE); G PROTEIN COUPLED RECEPTOR; GLUTAMATE RECEPTOR 3; GLUTAMATE RECEPTOR AGONIST; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMIC ACID; GUANINE NUCLEOTIDE BINDING PROTEIN; LIGAND; METABOTROPIC RECEPTOR 3;

ALLOSTERISM; ARTICLE; ASSAY; CALCIUM MOBILIZATION; CELL STRAIN HEK293; CONCENTRATION RESPONSE; DEVICE; DRUG RESEARCH; DRUG TARGETING; FLUORESCENCE IMAGING; FLUORESCENT IMAGING PLATE READER; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION;

ALLOSTERIC REGULATION; CELLS, CULTURED; HEK293 CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LIGANDS; RECEPTORS, METABOTROPIC GLUTAMATE; STRUCTURE-ACTIVITY RELATIONSHIP;

RATTUS; TETRA;

EID: 79960662881     PISSN: 13862073     EISSN: 18755402     Source Type: Journal    
DOI: 10.2174/138620711796367184     Document Type: Article

References (30)

1. Christopoulos, A. Allosteric binding sites on cell-surface receptors: Novel targets for drug discovery. Nat. Rev. Drug Discov., 2002, 1(3), 198-210. (Pubitemid 37361423)
2. Schroeder, K. S.; Neagle, B. D. FLIPR: A new instrument for accurate, high throughput optical screening. J. Biomolecular Screening, 1996, 1(2), 75-80. (Pubitemid 126677323)
3. Offermanns, S.; Simon, M. I. G alpha 15 and G alpha 16 couple a wide variety of receptors to phospholipase C. J. Biol. Chem., 1995, 270(25), 15175-15180.
4. Coward, P.; Chan, S. D.; Wada, H. G.; Humphries, G. M.; Conklin, B. R. Chimeric G proteins allow a high-throughput signaling assay of Gi-coupled receptors. Anal. Biochem., 1999, 270(2), 242-248. (Pubitemid 29252535)
5. May, L. T.; Leach, K.; Sexton, P. M.; Christopoulos, A. Allosteric modulation of G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol., 2007, 47, 1-51. (Pubitemid 46277033)
6. Conn, P. J.; Christopoulos, A.; Lindsley, C. W. Allosteric modulators of GPCRs: A novel approach for the treatment of CNS disorders. Nat. Rev. Drug Discov., 2009, 8(1), 41-54.
7. Niswender, C. M.; Johnson, K. A.; Weaver, C. D.; Jones, C. K.; Xiang, Z.; Luo, Q.; Rodriguez, A. L.; Marlo, J. E.; de Paulis, T.; Thompson, A. D.; Days, E. L.; Nalywajko, T.; Austin, C. A.; Williams, M. B.; Ayala, J. E.; Williams, R.; Lindsley, C. W.; Conn, P. J. Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4. Mol. Pharmacol., 2008, 74(5), 1345-1358.
8. NIH Chemical Genomics Center Assay Guidance Manual: FLIPR™ Assays to Measure GPCR and Ion Channel Targets. http://www.ncgc.nih.gov/guidance/ section9.html#types-of-fliprformats (Accessed May 10, 2010).
9. Krivoy, A.; Fischel, T.; Weizman, A. The possible involvement of metabotropic glutamate receptors in schizophrenia. Eur. Neuropsychopharmacol., 2008, 18(6), 395-405.
10. Harrison, P. J.; Lyon, L.; Sartorius, L. J.; Burnet, P. W. J.; Lane, T. A. The group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): Expression, function and involvement in schizophrenia. J. Psychopharmacology, 2008, 22(3), 308-322. (Pubitemid 351847454)
11. Conn, P. J.; Lindsley, C. W.; Jones, C. K. Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol. Sci., 2009, 30(1), 25-31.
12. Dunayevich, E.; Erickson, J.; Levine, L.; Landbloom, R.; Schoepp, D. D.; Tollefson, G. D. Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology, 2008, 33(7), 1603-1610. (Pubitemid 351684700)
13. Galici, R.; Jones, C. K.; Hemstapat, K.; Nong, Y.; Echemendia, N. G.; Williams, L. C.; de Paulis, T.; Conn, P. J. Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice. J. Pharmacol. Exp. Ther., 2006, 318(1), 173-185.
14. Sanacora, G.; Zarate, C. A.; Krystal, J. H.; Manji, H. K. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat. Rev. Drug Discov., 2008, 7(5), 426-437. (Pubitemid 351619114)
15. Patil, S. T.; Zhang, L.; Martenyi, F.; Lowe, S. L.; Jackson, K. A.; Andreev, B. V.; Avedisova, A. S.; Bardenstein, L. M.; Gurovich, I. Y.; Morozova, M. A.; Mosolov, S. N.; Neznanov, N. G.; Reznik, A. M.; Smulevich, A. B.; Tochilov, V. A.; Johnson, B. G.; Monn, J. A.; Schoepp, D. D. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized Phase 2 clinical trial. Nat. Med., 2007, 13(9), 1102-1107. (Pubitemid 47517511)
16. Fell, M. J.; Svensson, K. A.; Johnson, B. G.; Schoepp, D. D. Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2- sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039). J. Pharmacol. Exp. Ther., 2008, 326(1), 209-217. (Pubitemid 351872145)
17. Olszewski, R. T.; Bukhari, N.; Zhou, J.; Kozikowski, A. P.; Wroblewski, J. T.; Shamimi-Noori, S.; Wroblewska, B.; Bzdega, T.; Vicini, S.; Barton, F. B.; Neale, J. H. NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR. J. Neurochem., 2004, 89(4), 876-885. (Pubitemid 38684735)
18. Egan, M. F.; Straub, R. E.; Goldberg, T. E.; Yakub, I.; Callicott, J. H.; Hariri, A. R.; Mattay, V. S.; Bertolino, A.; Hyde, T. M.; Shannon-Weickert, C.; Akil, M.; Crook, J.; Vakkalanka, R. K.; Balkissoon, R.; Gibbs, R. A.; Kleinman, J. E.; Weinberger, D. R. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc. Natl. Acad. Sci. USA, 2004, 101(34), 12604-12609. (Pubitemid 39122071)
19. Tan, H. Y.; Chen, Q.; Sust, S.; Buckholtz, J. W.; Meyers, J. D.; Egan, M. F.; Mattay, V. S.; Meyer-Lindenberg, A.; Weinberger, D. R.; Callicott, J. H. Epistasis between catechol-O-methyltransferase and type II metabotropic glutamate receptor 3 genes on working memory brain function. Proc. Natl. Acad. Sci. USA, 2007, 104(30), 12536-12541. (Pubitemid 47206173)
20. Corti, C.; Crepaldi, L.; Mion, S.; Roth, A. L.; Xuereb, J. H.; Ferraguti, F. Altered dimerization of metabotropic glutamate receptor 3 in schizophrenia. Biol. Psychiatry, 2007, 62(7), 747-755. (Pubitemid 47374649)
21. Corti, C.; Battaglia, G.; Molinaro, G.; Riozzi, B.; Pittaluga, A.; Corsi, M.; Mugnaini, M.; Nicoletti, F.; Bruno, V. The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/neuroprotection. J. Neurosci., 2007, 27(31), 8297-8308. (Pubitemid 47219630)
22. Witkin, J. M.; Marek, G. J.; Johnson, B. G.; Schoepp, D. D. Metabotropic glutamate receptors in the control of mood disorders. CNS Neurol. Disord. Drug Targets, 2007, 6(2), 87-100. (Pubitemid 46681770)
23. Siehler, S.; Guerini, D. Novel GPCR screening approach: Indirect identification of S1P receptor agonists in antagonist screening using a calcium assay. J. Recept Signal Transduct. Res., 2006, 26(5-6), 549-575. (Pubitemid 44849905)
24. Desai, M. A.; Burnett, J. P.; Mayne, N. G.; Schoepp, D. D. Cloning and expression of a human metabotropic glutamate receptor 1 alpha: Enhanced coupling on co-transfection with a glutamate transporter. Mol. Pharmacol., 1995, 48(4), 648-657.
25. Warrior, U.; Gopalakrishnan, S. M.; Traphagen, L.; Freiberg, G.; Towne, D.; Humphrey, P.; Kofron, J.; Burns, D. J. Maximizing the identification of leads from compound mixtures. Lett. Drug Des. Discov., 2007, 4(3), 215-223. (Pubitemid 46474163)
26. Hann, M.; Hudson, B.; Lewell, X.; Lifely, R.; Miller, L.; Ramsden, N. Strategic pooling of compounds for high-throughput screening. J. Chem. Inf. Comput. Sci., 1999, 39(5), 897-902.
27. Acher, F. Metabotropic Glutamate Receptors: Molecular Pharmacology. http://www.tocris.com/pdfs/pdf-downloads/Metabotropic-Glutama te-Receptors-Review.pdf (Accessed October 30, 2009)
28. Schoepp, D. D.; Jane, D. E.; Monn, J. A. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology, 1999, 38(10), 1431-1476. (Pubitemid 29457728)
29. Schwartz, T. W.; Holst, B. Allosteric enhancers, allosteric agonists and ago-allosteric modulators: Where do they bind and how do they act? Trends Pharmacol. Sci., 2007, 28(8), 366-373. (Pubitemid 47087971)
30. Hemstapat, K.; de Paulis, T.; Chen, Y.; Brady, A. E.; Grover, V. K.; Alagille, D.; Tamagnan, G. D.; Conn, P. J. A novel class of positive allosteric modulators of metabotropic glutamate receptor subtype 1 interact with a site distinct from that of negative allosteric modulators. Mol. Pharmacol., 2006, 70(2), 616-626. (Pubitemid 44092322)